Covid-19 roundup: Re­searchers call out Gilead for di­ver­si­ty of remde­sivir tri­als in NE­JM; Mex­i­co in vac­cine dose, ...

2 days ago
Coronavirus

Mar­tin Shkre­li's in­fa­mous Dara­prim falls off top 20 most ex­pen­sive drugs list

2 days ago
Pharma

No­vo backs 'break­through' an­ti­fun­gal play­er's $60M round — with a fo­cus on rare mold in­fec­tions

2 days ago
Venture

UP­DAT­ED: Mod­er­na of­fers steep dis­count in US sup­ply deal — but still takes the crown with close to $2.5B in vac­cine ...

2 days ago
Coronavirus

Har­mo­ny Bio­sciences sets terms on $100M IPO; FDA ac­cepts a Pro­tal­ix BLA for re­view

3 days ago
Protocols

Ful­crum stum­bles in PhII of old GSK drug, send­ing shares tum­bling

3 days ago
R&D

Ei­sai is cre­at­ing a new US cor­po­rate, R&D HQ in Roche’s old Nut­ley, NJ cam­pus

3 days ago
Pharma

FDA gives thumbs-down on hear­ing loss drug, cit­ing man­u­fac­tur­ing is­sues, and sends Fen­nec stock reel­ing

3 days ago
Regulatory

Plot­ting to be the Bridge­Bio of AI, Atom­wise lands $123 mil­lion Se­ries B for hype-heavy plat­form

3 days ago
Venture
AI

UP­DAT­ED: End­points News ranks all 28 play­ers in the Covid-19 vac­cine race. Here's how it stacks up to­day

3 days ago
Coronavirus
In Focus

Per­cep­tive births its first in-house start­up — and it's a Chi­na play

3 days ago
Startups
Deals

Lig­and scoops up Pfenex for up to $516M, adding pro­teins to their an­ti­body chick­ens and de­liv­ery tech

3 days ago
Deals
R&D

Fir­dapse fails PhI­II for myas­the­nia gravis as Cat­a­lyst keeps look­ing for ex­pand­ed la­bel

3 days ago
R&D

Covid-19 roundup: Pfiz­er-backed BioN­Tech plans to seek FDA OK for a new vac­cine 'as ear­ly as' Oc­to­ber — ahead of ...

3 days ago
Coronavirus

UP­DAT­ED: Hunt­ing a block­buster, Bay­er forges an $875M-plus M&A deal to ac­quire women’s health biotech

3 days ago
Deals

UP­DAT­ED: Rea­ta sug­gests Friedre­ich's atax­ia pro­gram could be de­layed, send­ing stock plung­ing

3 days ago
Regulatory

Vi­da Ven­tures co-leads Dyne's $115M megaround for next-gen oli­go ther­a­pies aimed square­ly at mus­cles

4 days ago
Venture

Eli Lil­ly teams with Pieris on HER2+ tu­mors; Op­di­vo + Yer­voy best chemo in mesothe­lioma

4 days ago
Protocols

In­novent and Eli Lil­ly chal­lenge Mer­ck­'s mega-block­buster Keytru­da in non-small cell lung can­cer field

4 days ago
R&D

Anap­tys­Bio's etokimab pro­vides more dis­ap­point­ing re­sults, rais­ing ques­tions about com­pound's fu­ture

4 days ago
R&D

Spark Ther­a­peu­tics nabs new CMO from Genen­tech, fill­ing a ma­jor post-merg­er de­par­ture

4 days ago
People

The du­velis­ib hot pota­to is tossed to a new own­er as Ve­rastem looks to re­or­ga­nize around the pipeline

4 days ago
Deals
R&D

Phase III read­outs spell dis­as­ter for Genen­tech’s lead IBD drug

4 days ago
R&D

Covid-19 roundup: Cure­Vac beefs up its uni­corn IPO dreams as bil­lion­aire own­er takes this Covid-19 mR­NA play­er on a ...

4 days ago
Outsourcing
Pharma
First page Previous page 12345 Next page Last page